Co-Morbidities of Psoriasis: Cardiovascular and Metabolic Syndrome, …

Alan Menter

PsO, PsA & Spondyloarthritis: Shared Cellular Immunopathology, the E…

Cleveland Clinic Department of Rheumatic and Immunologic Disease

D. Mcgonagle

The Clinical Heterogeneity of Psoriatic Arthritis in Adults

Dafna Gladman

Axial Disease in Psoriatic Arthritis: Clinical Presentation, Genetic…

Philip Helliwell

IL-23 Biologics: How Do These Inhibitors' Safety and Efficacy Compar…

Leon Kircik

Guselkumab and Reductions in Fatigue Severity in Patients With PsA: …

Laure Gossec

2021 Updates on PsA Management: Diagnosis, Assessment, and Current/ …

Cleveland Clinic Department of Rheumatic and Immunologic Disease

E. Husni

Psoriatic Arthritis Panel Discussion: ACR21

RheumNow

R. Tate, M. Ramahi, P. Castillo, A. Chan, O. Petryna, R. Chao, R. Conway

Instruments Measuring Physical Function for Active PsA: Overview of …

ACR Convergence 2021 Coverage

A. Ogdie

Interdisciplinary Approaches to Psoriatic Disease: Combining Clinics…

Joseph Merola

Psoriatic Disease: Risk Factors in People of Color

National Psoriasis Foundation

S. Desai

Efficacy and Safety of Phase III Trial of Guselkumab in PsA Patients…

RheumNow

Y. Yusof, L. Coates

A Year in Review: What Was New in Psoriasis Treatment in 2021 and Wh…

Joseph Merola

Treatment Responses in Patients With Psoriatic Arthritis Axial Disea…

Alexis Ogdie

Controversies in Psoriatic Arthritis: Methotrexate, Domain-Based App…

RheumNow

J. Cush, D. Gladman, J. Merola, P. Nash, C. Ritchlin, J. Scher

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselk…

The Journal of Rheumatology

P. Rahman